NCT06059326View on ClinicalTrials.gov

Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 22, 2019

Primary Completion Date

November 5, 2019

Study Completion Date

November 5, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

HSK7653 10 mg

Tablet, HSK7653 10 mg Q2W, 12 weeks

DRUG

HSK7653 25 mg

Tablet, HSK7653 25 mg Q2W, 12 weeks

DRUG

HSK7653 50 mg

Tablet, HSK7653 50 mg Q2W, 12 weeks

DRUG

Placebo

Tablet, 0 mg Q2W, 12 weeks

Trial Locations (1)

100044

Peking university people's hospital, Beijing

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT06059326 - Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM | Biotech Hunter | Biotech Hunter